Posted by Michael Wonder on 16 Jul 2025
BeOne bets Tevimbra will beat rivals to PD-1 reimbursement in Korea
15 July 2025 - BeOne Medicines (formerly BeiGene) is doubling down on Korea’s immunotherapy market with an early access push for its PD-1 inhibitor Tevimbra, aiming to undercut entrenched rivals with a pricing and reimbursement strategy tailored to local needs.
“We are confident that Tevimbra will enter the reimbursement system faster than any immune checkpoint inhibitor previously launched in Korea,” BeOne Medicines Korea General Manager Yang Ji-hye said at a press briefing on Tuesday. “Access is part of innovation. We are committed to ensuring this drug reaches the patients who need it, without delay.”
